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Abstract
Possible links between PARP-1 and HIV-1 have been previously reported but the
role of this protein during viral infection has remained elusive. Based on the high
evolutionary conservation of PARP-1, from Drosophila to humans, we have been able to
counteract the difficulties related with the functional redundancy manifested in the PARP
family by studying the influence of PARP-1 on the expression of an endogenous retrovirus
using the chicken B lymphoblastoid cell line DT40, this cell line exhibits low PARP-1
functional redundancy and is viable after PARP-1 knockout. We have determined that the
transcription level of the endogenous retrovirus RAV-1 is significantly higher in PARP-1
KO cells than in PARP-1 WT cells but the WT phenotype is restored when PARP-1 KO
cells are engineered to re-express human PARP-1 (PARP-1 h-1 cells). Such results
suggest that PARP-1 is a cell factor with a negative influence in retroviral transcription
and led us to investigate the role of this protein in HIV replication within human cells.
Using PARP-1 KD and control human CD4+ T cell lines we have been able to
demonstrate that PARP-1 deficiency enhances the replication of the HIV-1. The effect of
PARP-1 deficiency in HIV-1 replication in human cells was observed upon
pharmacological inhibition of PARP-1. Importantly, inhibitors targeting the zinc finger
domains of PARP-1, implicated in DNA binding, but not those inhibiting its catalytic activity
caused an enhancement of HIV replication. These results highlight the relevance of the
DNA binding domain of PARP-1 in this effect on HIV-1 replication. Intriguingly, in contrast
to its effect on HIV-1 replication, PARP-1 antagonism was not affected by a single-round
of infection with an HIV-1 lentiviral vector. These replication incompetent viruses only
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recapitulate the early events of the viral life cycle, leading us to suggest that PARP-1 does
not play a role during the early stages of the HIV life cycle.
Considering that primary CD4+ T cells are the natural target of the HIV-1 virus, we
finally decided to study the role of PARP-1 in HIV-1 replication in these cells. The use of
PARP-1 inhibitors and a novel cell model to study HIV latency, allowed us to conclude
that in primary cells the presence of PARP-1 negatively modulates HIV-1 replication. This
finding implies that PARP-1 could be a restriction factor for HIV replication in human cells.
Our data indicates the possibility of using PARP-1 as a new point of therapeutic
intervention against the HIV virus in humans.
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CHAPTER 1: Introduction
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1.1.

HIV Overview
Acquired Immune Deficiency Syndrome (AIDS) was first recognized as a new

disease in 1981 when increasing numbers of young homosexual men succumbed to
unusual opportunistic infections and rare malignancies[1]. A retrovirus, now termed
human immunodeficiency virus (HIV), was subsequently identified as the causative agent
of what has since become one of the most devastating infectious diseases to have
emerged in recent history [2, 3]. Currently there are more than 35 million people living
with HIV and nearly 39 million people with AIDS have died worldwide since the epidemic
began.
Human immunodeficiency virus isolates are currently grouped into two types, HIVtype 1 (HIV-1) and HIV-type 2 (HIV-2). The worldwide main agent of AIDS is HIV-1, while
HIV-2 is restricted to some regions of Western and Central Africa[4].
HIV is a genetically related member of the Lentivirus genus of the Retroviridae
family. This family has a unique enzyme called reverse transcriptase (RT) that converts
viral RNA into DNA upon viral entry into the cell. The genome of HIV-1 contains two
identical copies of single stranded positive RNA molecules which encode nine open
reading frames (Figure 1.1) that produce 15 proteins. Structural proteins ensemble with
two copies of the viral RNA genome into an enveloped virus of 0.1 microns in diameter
(Figure 1.2).
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Figure 1.1 Depiction of the HIV nine open reading frames[5]

The gag gene encodes the structural proteins of the core (p24, p7, p6) and matrix
(p17), the env gene encodes the viral envelope glycoproteins gp120 and gp41, which
recognize cell surface receptors, and the pol gene encodes for enzymes crucial in viral
replication, which are the reverse transcriptase that converts viral RNA into DNA, the
integrase (IN) that incorporates the viral DNA into host chromosomal DNA and the
protease (PR) that cleaves large Gag and Pol protein precursors into their components.
HIV-1 encodes six additional proteins; Tat and Rev, two regulatory proteins, and four so
called accessory proteins, Vif, Vpr, Vpu and Nef [6]. Tat protein is expressed very early
after infection and promotes the expression of HIV genes by facilitating transcriptional
elongation while Rev ensures the export from nucleus to cytoplasm of the correctly
processed viral messengers and genomic RNA. The function of the other accessory HIV
proteins is less well understood; it is believed that the Vpr protein is involved in the arrest
of the cell cycle and counteraction of the HIV-1 restriction factor SAMHD1. This protein
also enables the reverse transcribed DNA to gain access to the nucleus in non-dividing
cells such as macrophages. Vpu is a protein necessary for the correct release of virus
particle by counteracting the antiviral protein tetherin, whereas Vif enhances the
infectiveness of progeny virus particles by triggering degradation of the antiviral protein
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APOBEC3G. Finally, the Nef protein has multiple functions including cellular signal
transduction and the down regulation of the CD4 receptor on the cell surface to allow
virus budding in the late stages of the virus replication cycle.

Figure 1.2 Schematic of HIV-1 [5]
HIV viral particles contain two copies of non-covalently linked, unspliced, positive-sense single-stranded
RNA molecules associated with structural and accessory proteins. Structural proteins are encoded by long
open reading frames: Gag (MA, CA, SP1, NC, SP2, and P6), Env (gp41, gp120), and Pol (PR, RT, IN),
while accessory and regulatory proteins are encoded by smaller open reading frames: Vif, Vpr, Nef, Tat,
Rev and Vpu.
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1.2.

HIV Life Cycle
The life cycle of HIV-1 can be divided into two phases: the early stage occurs

between entry into the host cell and integration into its genome, and the late phase occurs
from the state of integrated provirus to full viral replication (Figure 1.3).

Figure 1.3 The HIV life cycle [7].
The early events of HIV-1 replication in infected cells include binding of the virus to a target cell, fusion and
entry of the viral core into the cytosol, reverse transcription of the viral genome to produce a viral copy
cDNA, uncoating of the viral core and nuclear entry, followed by integration of the viral genome into the
host chromosome. The late phase of the cycle consists of transcription of the integrated provirus, transport
of spliced and unspliced viral RNA molecules to the cytosol, translation of the viral RNA to produce viral
proteins, assembly of these proteins with unspliced viral RNA molecules, budding of new immature viral
particles from the cells and finally the maturation of these particles to produce replication competent viral
particles.
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Viral entry involves the fusion of viral and cellular membranes through successive
interactions with CD4 and CXC chemokine receptor type 4 (CXCR4) or CC chemokine
receptor type 5 (CCR5) [8]. These interactions induce conformational changes in gp120
and gp41 that lead to the exposure of the fusion peptide at the N-terminus of gp41. The
fusion peptide insertion into the target membrane triggers the fusion of viral and host lipid
bilayers and subsequent release of the viral core into the target cell cytoplasm. Once in
the cell cytosol the virus is faced with the challenge of reverse transcribing the viral RNA
with the concert of RT and transporting the proviral precursor to the nucleus for
integration. In this process, the viral core is rearranged to form the reverse transcription
complex (RTC). This results in changes to the viral protein composition of the original
core and is facilitated by host cell protein involvement. Completion of RTC maturation and
reverse transcription of the viral genome generates the pre-integration complex (PIC)
containing a linear double-stranded cDNA (dscDNA) molecule with terminal direct repeats
and blunt ends[9], which is integration competent.
HIV uncoating, defined as the loss of viral capsid that occurs at the nuclear
envelope, is also an obligatory step that accompanies the transition between RTCs and
PICs. The study of the nature and timing of HIV-1 uncoating has been paved with
difficulties, particularly as a result of the vulnerability of the capsid assembly to
experimental manipulation. Nevertheless, recent studies of capsid structure, retroviral
restriction and mechanisms of nuclear import, as well as the recent expansion of technical
advances in genome-wide studies and cell imagery approaches, have substantially
changed our understanding of HIV uncoating. Although early work suggested that
uncoating occurs immediately following viral entry in the cell, thus attributing a trivial role
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for the capsid in infected cells, recent data suggest that uncoating occurs several hours
later, in close proximity to the nuclear pore, and that capsid has an all-important role in
the cell that it infects: for transport towards the nucleus, reverse transcription and nuclear
import [10].
Viral trafficking of the PIC is mediated through microtubules by retrograde transport
and uses dynein [11]. At the nuclear pore complex, the PIC enables the transport of
dscDNA through the pore, thereby allowing the infection of resting, non-dividing cells.
Inside the nucleus, the viral dscDNA either integrates into the host cell chromosomes or
remains in an unintegrated state, like linear cDNA or DNA circles[12]. Host factors such
as LEDGF/p75 are key molecules that facilitate HIV-1 integration. LEDGF is a
transcriptional co-activator that binds HIV IN and acts as a tethering factor to promote
viral integration [13]. After integration, the LTR-flanked provirus behaves as a cellular
gene: the 5′ LTR operates like any eukaryotic promoter and the 3′ LTR acts as the
polyadenylation and termination site [14].
Activation of the T cell induces binding of the transcriptional pre-initiation complex
to enhancer elements in the 5′ LTR proximal promoter. This complex gathers essential
host transcription factors, such as nuclear factor-κB (NF-κB)[15], nuclear factor of
activated T cells (NFAT)[16], and specificity protein 1 (SP1)[17], among others. These
enhancer proteins transmit activation signals to basal factors belonging to the general
transcription machinery and promote binding of RNA polymerase II (RNAPII) to the TATA
box to initiate mRNA transcription. A 59-nucleotide stem-loop structure termed the
transactivation response element (TAR) is then formed at the 5′ end of the nascent viral
transcript, creating a binding site for the viral trans-activator Tat [18]. The Tat–TAR
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interaction promotes efficient elongation of viral transcripts by recruiting cellular factors
that increase the functional capacity of RNAPII, such as positive transcription elongation
factor b (PTEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin
T1[19, 20]. Efficient elongation of viral transcripts allows the synthesis of mRNA, which is
further processed by the regulatory protein Rev. Rev is a viral RNA-binding factor that
regulates the nucleo-cytosolic transport and splicing of viral mRNA species [21].
Once new viral proteins are synthetized in the cytosol of the infected cell, the last
event in the HIV life cycle, called virion morphogenesis takes place. This essential step
can be divided into three stages: assembly, wherein the virion is created and essential
components are packaged; budding, wherein the virion crosses the plasma membrane
and obtains its lipid envelope; and maturation, wherein the virion changes structure and
becomes infectious [22].
HIV-1 virion assembly occurs at the plasma membrane, within specialized
membrane microdomains. The HIV-1 Gag (and Gag-Pro-Pol) polyprotein itself mediates
all of the essential events in virion assembly, including binding the plasma membrane,
making the protein–protein interactions necessary to create spherical particles,
concentrating the viral Env protein, and packaging the genomic RNA via direct
interactions with the RNA packaging sequence (termed Ψ). These events all appear to
occur simultaneously at the plasma membrane, where conformational change(s) within
Gag couples membrane binding, virion assembly, and RNA packaging. Although Gag
itself can bind membranes and assemble into spherical particles, the budding event that
releases the virion from the plasma membrane is mediated by the host ESCRT
(endosomal sorting complexes required for transport) machinery [22].
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The virion acquires its lipid envelope and Env protein spikes as it buds from the
plasma membrane. Unlike Gag, Env is an integral membrane protein. It is inserted cotranslationally into ER membranes and then travels through the cellular secretory
pathway where it is glycosylated, assembled into trimeric complexes, processed into the
trans-membrane (TM; gp41) and surface (SU; gp120) subunits by the cellular protease
furin, and delivered to the plasma membrane via vesicular transport [22].
The Gag polyprotein initially assembles into spherical immature particles, in which
the membrane-bound Gag molecules project radially toward the virion interior. As the
immature virion buds, PR is activated and cleaves Gag into its constituent MA, CA, NC,
and p6 proteins, thereby also releasing the spacer peptides 1 (SP1) and SP2. Proteolysis
is required for conversion of the immature virion into its mature infectious form. Like other
retroviral proteases, HIV-1 PR is a dimeric aspartic protease that recognizes specific sites
within Gag and cleaves them in an ordered fashion. Gag proteolysis triggers major
changes which include condensing and stabilizing the dimeric RNA genome, assembling
the conical capsid about the genomic RNA–nucleocapsid-enzyme complex, and
preparing the virion to enter, replicate, and uncoat in the next host cell. Thus, viral
maturation can be viewed as the switch that converts the virion from a particle that can
assemble and bud from a producer cell into a particle that can enter and replicate in a
new host cell [23].
1.3.

PARP-1 Structure and Functions
ADP-ribosyltransferases (ARTs) comprise a family of structurally conserved

enzymes that catalytically cleave NAD+ and transfer the ADP-ribose moiety to acceptor
residues of target proteins [24]. Poly (ADP-ribosyl) polymerases (PARPs) are a subset of
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the ART family that continue this reaction to create long chains of linear and/or branched
poly (ADP-ribose) (PAR) (Figure 1.4) (Table . 1.1). Currently, only the first six members
of this family (ARTs 1–6) are regarded as having poly ADP-ribosylation activity: PARP-1,
PARP-2, PARP-3, PARP-4, PARP-5a, and PARP-5b (Figure 1.5). The remaining ARTs
7–17, although originally considered PARPs (PARPs 6–16) [25], are only capable of
producing mono-ADP-ribose modifications and are referred to as mono-ARTs (MARTs)
[26].
Poly (ADP-ribose) polymerases are multi-domain proteins that are related through
their highly conserved ART domain. Outside of the ART domain, distinct domain
architectures quickly differentiate the structure and function of each PARP. The catalytic
domain crystal structures have been solved for all current PARPs except for PARP-4. The
crystal structures of some non-catalytic domains of PARPs have been solved, although
there is no crystallographic data on any full-length PARP [27].
PARP-1 and PARP-3 are the only PARPs for which structures of all domains are
known. PARP-1 is a 116 kDa protein (1014 amino acids in mice and humans) with a
modular domain architecture comprising three main domains: an N-terminal DNA-binding
domain (DBD), a central automodification domain and a C-terminal catalytic domain. The
DBD contains three zinc-fingers (Zn1, Zn2, and Zn3), which have different roles in DNA
binding, interdomain cooperation, chromatin compaction and protein–protein interactions,
and a nuclear localization signal (NLS). In the central automodification domain glutamate,
aspartate and lysine residues serve as putative acceptors for auto (ADP-ribosyl)ation, a
leucine zipper motif mediates homo- or heterodimerization and a breast cancerassociated protein C-terminal (BRCT) motif mediates protein–protein interactions.
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Adjacent to the catalytic domain a tryptophan-, glycine-, and arginine-rich WGR domain
has also been shown to be required for DNA-damage induced PAR synthesis. The
catalytic domain contains the ‘‘PARP signature’’ sequence required for the catalysis of
PAR synthesis (Figure 1.6) [28].

Figure 1.4 Poly (ADP) ribose (pADPr) metabolism [28]
PARP proteins use NAD+ as their substrate to modify acceptor proteins with adenosine diphosphate-ribose (ADPr)
modifications while PARG is the major enzyme responsible for the catabolism of poly (ADP-ribose) polymers.
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Table 1.1 PARP family member; enzymatic activities and functional domains [29]
The PARP family members differ not only in subcellular localization and structure but also in enzymatic activity since
some of them are only capable of producing mono-ADP-ribose modifications (M) while others have poly ADPribosylation activity (P).
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Figure 1.5 Domains of human PARPs [26]
PARP-1 domains have been crystalized as well as the catalytic and some non-catalytic domains of other PARPs except
PARP-4. The ADP-ribosyltransferase domain (ART) is conserved among the family. PARPs 1–4 contain a helical
domain (HD) that is implicated in allosteric regulation. PARPs 1–3 have a WGR domain related with DNA-dependent
catalytic activation. Some other domains like the breast cancer susceptibility protein-1 C-terminus (BRCT) domain,
found in DNA repair and checkpoint proteins, is present in PARP-1 and PARP-4. Zinc-fingers are part of the DNA
binding domain of PARP-1. Zn1 and Zn2 of PARP-1 are important in binding DNA, while the third zinc-finger (Zn3) is
important in DNA-dependent catalytic activation.
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PARP-1, the best studied protein in the PARP family, is a protein that is found in
most eukaryotes except for yeast [30]. After the histones, it is the most abundant nuclear
protein (one molecule of enzyme per 1000 bp of DNA [31]), and its activity accounts for
90% of PAR production in the cell[32]. The pool of freely diffusible nucleoplasmic PARP1 is very small, with most of the PARP1 protein bound to chromatin and accumulated in
nucleoli [33-37]. The distribution of PARP1 in chromatin is nonrandom, occurring in
characteristic profiles specific for distinct cell types[38].

Figure 1.6 Molecular structure of PARP-1 [28]
The numbers relate to the boundaries of the domains in human PARP. NLS, nuclear localization signal;
HTH, helix–turn–helix motif; LZ, leucine-zipper motif.

PARP-1 plays essential roles in the cell, including DNA repair, translation,
transcription, telomere maintenance, and chromatin remodeling [38]. It regulates a broad
range of essential nuclear events, including two complementary processes (1) regulation
of protein–nucleic acid interactions by means of protein shuttling and (2) utilizing polyADP-ribose as an anionic matrix for trapping, recruiting, and scaffolding proteins [38].
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PARP-1 is active as a dimer [39, 40]. ADP-ribose modification of its dimerization
domain through automodification causes PARP-1 dimers to dissociate from both each
other and active chromatin while losing enzymatic activity.
PARylation carries out a plethora of cellular functions, which explains the high
abundance of PARP-1 molecules in the cells; only a small fraction of them are present in
their PARylated form. The presence of numerous inactive PARP molecules guarantees
an immediate response to cell signaling or DNA damage [41, 42]. In fact, when cells are
adapting to stress, the level of long ADP-ribose polymers (pADPr) is dramatically
increased; however, they are quickly degraded as their half-life goes down from 6–7 min
to a few seconds [43].
DNA strand breaks remarkably increase basal activity of PARP-1 (up to 500 times)
[44]. Compelling evidence suggest that PARP-1, through its physical association with or
by poly (ADP-ribosyl)ation of partner proteins, regulates chromatin structure, DNA
metabolism and gene expression.
Poly(ADP-ribose) polymerases acts in a wide variety of situations by locally
derepressing gene transcription or other chromosomal processes that are blocked by the
tight binding of histones and other inhibitory chromatin proteins. Two mechanisms by
which PARP1 may loosen chromatin have been suggested by biochemical studies. First,
PARP1 may catalyze the transfer of ADP-ribose moieties from NAD to abundant nuclear
proteins, such as histones. Indeed, in vitro modification by pADPr destabilizes the
interaction of chromatin components with DNA including histones [45, 46]. Second, the
formation of long pADPr residues on PARP1 itself may contribute to loosening [36, 47].
Many chromatin proteins exhibit high affinity for pADPr and may relocate from chromatin
and bind to automodified PARP1 at the sites of activation. Alternatively, the network of
pADPr may generate an environment conducive to the formation of active loci, organizing
the processes of transcribing, packing, and processing RNA. The observation that
nucleoli disintegrate following PARP1 inhibition favors the latter model.
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PARP1 can modify proteins both covalently and noncovalently; that is to say, a
protein’s function or localization can be dramatically changed, either by the covalent
attachment of poly-ADP-ribose or noncovalent interaction with it. Approximately thirty
proteins have been identified, both in vivo and in vitro, as covalent targets of pADPr[28].
These proteins include a broad range of components and regulators in key nuclear
processes: modulating chromatin structure, DNA synthesis, DNA repair, transcription, cell
cycle, and additional miscellaneous targets. Many proteins have been identified as having
strong noncovalent affinity for pADPr proteins, including histones, hnRNPs and various
others involved in DNA repair and checkpoints [48, 49]
PARP1 has also been found to poly-ADP-ribosylate TATA-binding protein (TBP),
Yin Yang 1, NFkappaB, Sp1, and CREB, resulting in their inability to bind DNA [50]

1.4.

PARP-1 DNA binding domain (DBD)
The N-terminal DBD extends from the initiator methionine to threonine 373 in

human PARP-1[51]. This domain has a molecular mass of approximately 42 kDa and
contains three zinc fingers (ZnF1, residues 6-91; ZnF2, residues 105-202 and ZnF3,
residues 224-360) and a bipartite nuclear localization signal (NLS, residues 207-226).
PARP zinc fingers are structurally and functionally unique, since they coordinate zinc
molecules with a Cys-Cys-His-Cys motif, they contain more residues than other zinc
fingers usually consisting on 12-13 residues, and they recognize altered structures in
DNA rather than particular sequences[52].
Although it has been suggested that ZnF1 recognizes double strand DNA breaks
(DSB) and that ZnF2 has a binding preference for single strand DNA breaks (SSB), both
fingers are required for full activation of PARP-1. It is, however, not well known how ZnF1
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and ZnF2 recognize diverse types of DNA structures. ZnF2 is linked to ZnF3 by a 26residue peptide. This zinc finger was identified in recent years as being involved in PARP1-PARP-1 homodimer formation. Zn3 mutants are not activated by DNA breaks,
indicating that functional homodimerization of PARP-1 through ZnF3 is required for
efficient activation of PARP-1 [53].
Mutational and deletion analysis of the ZnF1 and ZnF2 domains indicates a pivotal
role for the ZnF1 domain in PARP-1 DNA-dependent activity in vitro, whereas the ZnF2
domain is not essential, but perhaps plays a role in PARP-1 binding to particular damaged
DNA structures. A combination of mutations that simultaneously disrupts both the ZnF1
and ZnF2 domains interferes with PARP-1 interaction with chromatin in the absence of
DNA damage. This further highlight that PARP-1 interaction with DNA through the ZnF1
and ZnF2 domains can adapt to a range of DNA structures, including nucleosome-bound
conformations of continuous, undamaged DNA. The mode of interaction with DNA for the
ZnF1 and ZnF2 domains has been a notable deficiency in our understanding of PARP-1,
and the mechanism by which the ZnF1 domain specifically contributes to DNA-dependent
activation of PARP-1 is unknown[54].
In addition to the ZnF1 domain, the ZnF3 domain is also required to support DNAdependent PAR synthesis activity of the catalytic domain (Figure 1.7) [54]. The ZnF3
domain structure consists of a unique type of zinc-ribbon fold and a α-helical N-terminal
region. Importantly, the structure is entirely unrelated to the ZnF1 and ZnF2 domain
structures and is therefore expected to have a distinct function. Zinc-ribbon folds
frequently mediate protein-protein interactions; therefore, this is a likely role for the zincribbon fold of the ZnF3 domain. In the crystal structure, the C-terminal tail of the ZnF3
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domain forms an extensive interface between two ZnF3 monomers that are related by 2fold crystallographic symmetry. Although the isolated ZnF3 domain is a monomer in
solution, conserved residues are involved in forming the ZnF3 homodimer interface
suggesting that the ZnF3 domain might exist as a dimer in the DNA-activated state of
PARP-1.

Figure 1.7 Model for DNA damage-dependent activation of PARP-1 [54]
In the absence of DNA damage PARP-1 domains exist in an extended, ‘beads-on-a-string ‘conformation.
The HD serves as a modulator of PARP-1 activity, holding the ART in a rigid conformation. Upon detecting
DNA damage the Zn1, Zn3, and WGR domains collapse together, forming a network of interdomain
contacts that perturb the structure of the HD, displacing a ‘leucine switch’ that decreases the stability of the
catalytic domain and increases the catalytic activity. A more flexible, dynamic ART conformation is more
efficient to perform the multi-step synthesis of poly (ADP-ribose). The collapsed conformation positions the
automodification region adjacent to the catalytic domain, providing substrate specificity and contributing to
an enhanced rate of poly (ADP-ribose) production.
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Current models indicate that PARP-1 functions as a catalytic dimer; therefore, it
has been speculated that the ZnF3 dimer might participate in assembling two molecules
of PARP-1 for activation. There are several possible mechanisms by which the ZnF3
interdomain contact might regulate PARP-1 activity. The ZnF3 domain could bridge an
interaction between two PARP-1 domains, bringing them into the appropriate orientation
for an association necessary for PAR synthesis. Another possibility is that the Zn3
interdomain contact acts to orient the automodified region of PARP-1 for efficient addition
of PAR [27].
The ZnF3 domain is also an important element required for chromatin compaction
that leads to maximal repression of transcription by PARP-1. A potential mechanism is
homodimerization of two adjacent nucleosome-bound PARP-1 molecules. Several
studies show that the ZnF1-ZnF2 domains are necessary and sufficient for the
nucleosome binding property of PARP-1. The ZnF3 dimer observed in the crystal
structure is a possible candidate for mediating the homodimerization of PARP-1 on
chromatin. The fact that mutation of residues located at the ZnF3 dimer interface
compromises chromatin compaction is consistent with this hypothesis. However, earlier
studies indicated that the ZnF1-ZnF2-ZnF3 domains could not compact chromatin, but
when linked to the catalytic domain (CAT) the chromatin compaction capability of PARP1 was restored. These data underscore the possibility that both the ZnF3 domain and the
CAT domain are intricately associated in the homodimerization of PARP-1. An
appropriate model would be that ZnF1-ZnF2 domains are necessary for the binding of
PARP-1 to chromatin, whereas the ZnF3 and CAT domains are collectively required for
the dimerization of PARP-1. Rather than mediating homodimerization of chromatin bound
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PARP-1, the ZnF3 domain alternatively could be important for positioning other PARP-1
domains for full compaction of chromatin. The DNA binding domain and the CAT domain
of PARP-1 collaborate to induce chromatin compaction; therefore, a potential function of
the ZnF3 domain is to coordinate the activities of the ZnF1-ZnF2 domains and the CAT
domain [55].
The crystal structures for the individual human PARP-1 zinc fingers in complex
with blunt-ended duplex DNA, a potent stimulator of PARP-1 activity has been previously
studied. The ZnF1-DNA and ZnF2-DNA structures demonstrate a consistent mode of
interaction with DNA that is distinct from other known DNA binding factors. The ZnF1 and
ZnF2 domains bind to an uninterrupted segment of the phosphate backbone using a
region that have been termed the phosphate backbone grip, and they engage the
exposed nucleotide bases of DNA through a second region termed the base stacking
loop. Biochemical analysis demonstrates that the ZnF1 domain has relatively weak DNA
binding affinity, but this activity is required for activation of PARP-1. In contrast, the ZnF2
domain binds to DNA with much higher affinity yet is not essential for DNA-dependent
PARP-1 activation in vitro or in vivo[56]. The ZnF1-DNA complex structure combined with
mutational and structural analysis indicate that a specialized loop region of the ZnF1
domain is repositioned upon binding to DNA, and this situates key residues that contribute
to the activation of PAR synthesis in a DNA-dependent manner [57].
The ZnF1-DNA and ZnF2-DNA crystal structures provide the first views of PARPlike zinc fingers bound to DNA, revealing a bipartite mode of DNA interaction that contacts
sequence-independent features of the DNA structure: the sugar-phosphate backbone
and exposed nucleotide bases. PARP-1 binds to DNA structures containing damage such
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as single and double strand breaks; yet, it is interesting to note that the ZnF1 and ZnF2
domains do not contact the DNA at 3’ or 5’ terminus. Rather, the ZnF1 and ZnF2 domains
bind to exposed nucleotide bases that are indeed present in DNA structures containing
breaks, but would also be present in the undamaged, abnormal DNA structures that
PARP-1 binds, such as hairpin and cruciform DNA. Thus, the ZnF1-DNA and ZnF2-DNA
structures provide insights into how PARP-1 zinc fingers could interact with a variety of
DNA structures. The phosphate backbone grip as a rigid component of the DNA
interaction will engage uninterrupted 3-nucleotide segments of DNA backbone in a
consistent manner when engaging all types of DNA structure. The base stacking loop will
likely serve as a flexible component of the DNA interaction that will allow the zinc fingers
to adapt to variability in the DNA structures, with a common element being the interaction
between hydrophobic protein side chains and exposed DNA bases. Therefore the base
stacking loop of the ZnF1 domain is a critical and specific factor that regulates DNAdependent PARP-1 automodification activity [58].
It has been proposed that the base stacking loop interaction with DNA positions
specific ZnF1 residues that will form key contacts with other essential domains of PARP1, and these DNA-induced contacts contribute to PARP-1 DNA-dependent activity.
Importantly, the ZnF1 residues that are important for mediating PARP-1 activation are not
conserved in the ZnF2 domain, providing a molecular basis for ZnF1 specificity in
regulating PARP-1 activity. Consistent with this model, previous biochemical analysis of
PARP-1 DNA-dependent activity has demonstrated that the composition of duplex DNA
influences the level of PARP-1 activation. These variations in DNA structure influence the
positioning of the base stacking loop on DNA, and thus affect ZnF1 ability to efficiently
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form interdomain contacts that support DNA-dependent PARP-1 activity. Interdomain
contacts will ultimately impose structural changes in the PARP-1 catalytic domain that
increase enzymatic activity, or will promote an arrangement of PARP-1 domain
architecture that increases access to substrates [59].
The ZnF2 domain alone has substantial DNA binding affinity on its own, 100-fold
higher than that of the ZnF1 domain alone. The robust DNA binding affinity of the ZnF2
domain could be important for the rapid localization of PARP-1 to sites of DNA damage,
or the persistence of PARP-1 at damage sites, even though the ZnF2 domain is not strictly
required for PAR synthesis activity at sites of damage [60].
The relatively weak DNA binding affinity of the ZnF1 domain could be an important
feature for regulation of PARP-1 DNA dependent activity. A proteomic analysis of PARP1 phosphorylation sites identified Ser-41 of the ZnF1 domain as a site of modification,
and the phosphomimic S41E decreased PARP-1 recruitment and persistence at a
microirradiated region of the nucleus containing DNA damage, presumably by disrupting
ZnF1 interaction with DNA. Ser-41 is located on the base stacking loop adjacent to the
exposed DNA bases, and therefore should not be readily accessible to kinase activity
when the ZnF1 domain is bound to DNA. The weak DNA binding affinity of the ZnF1
domain would allow this surface to be accessible for phosphorylation a portion of the time,
supporting modification at this site as a mode of regulating PARP-1 function [61].
The analysis of ZnF1 and ZnF2 specific functions indicates that the ZnF2 domain
does not play a pivotal role in DNA-dependent activation of PARP-1. PARP-1 has
important functions outside of the DNA damage response, contributing to transcription as
both a general and specific regulator of gene expression. DNA-dependent PAR synthesis
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activity is not required for all of PARP-1 transcriptional activities. The ZnF2 domain could
serve specific roles in regards to PARP-1 function(s) in transcription. In this regard, the
higher DNA binding affinity of the ZnF2 domain might play a more important role.
Individual mutation of the ZnF1 and ZnF2 domains of human PARP-1 might reveal
specific functions for the zinc fingers in regulating PARP-1 transcriptional activities or
interaction with chromatin.
PARP-1 binds to chromatin and influences chromatin structure, and thus functions
as a DNA architectural protein. Interestingly, the manner in which PARP-1 zinc fingers
engage DNA bases using hydrophobic protein side chains is reminiscent of other DNA
architectural proteins that bind to distorted DNA structures, or induce DNA distortions
upon binding, such as high-mobility group protein HMG1 and TATA-binding protein.
Although the ZnF1 and ZnF2 domains are structurally distinct compared with both of
these DNA architectural proteins, there are likely to be common elements to how the
PARP-1 zinc fingers will engage exposed DNA bases in distorted DNA structures.
A critical distinction between the ZnF1 and ZnF2 domains and DNA architectural
proteins with known structures is that the hydrophobic residues of the ZnF1 and ZnF2
domains insert into the major groove of the DNA, rather than the minor groove. This is
best visualized by aligning a continuous B-form DNA helix to the duplex DNA contained
in the ZnF1-DNA complex. Due to the positioning of the base stacking loop in the major
groove of the DNA, it is expected that both the ZnF1 and ZnF2 domains will bind to DNA
distortions that expose nucleotide bases in the major groove, and therefore bend DNA
toward the minor groove. Interestingly, the structure of a tetramer of nucleosomes
demonstrates this type of major groove distortion in the linker DNA connecting
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nucleosomes, where PARP-1 is known to bind. Rigid body positioning of a PARP-1 zinc
finger on the nucleosomal linker DNA suggests that this type of major groove distortion
can better accommodate the base stacking loop in the major groove. This hypothetical
model provides insight into how PARP-1 zinc fingers are capable of interacting with
continuous, undamaged DNA structures [27, 62].
1.5.

PARP-1 in retroviral infection
Possible links between PARP-1 and retroviral infection have been reported

previously. In 1991, for example, Yamagoe et al. [63] observed a promotion of UV
irradiation-induced HIV-1 gene expression by PARP-1 inhibitors in HeLa cells at the
posttranscriptional level, although it is not yet known whether PARP-1 per se is indeed
involved in the promotion. Ha et al. [64] also reported in 2000 a role for PARP-1 in HIV-1
integration, after observing an abolishment of infection in PARP-1 knockout mice
fibroblasts, although Siva and Bushman [65] later tested the same model and concluded
that PARP-1 is not strictly required for retroviral infection because replication steps,
including integration, can proceed efficiently in its absence. More recently, Parent, M., et
al reported that PARP-1 is a host cellular factor that negatively regulates HIV-1
transcription through competitive binding to TAR RNA with Tat positive transcription
elongation factor b (p-TEFb) complex [66]. All these studies, flagged with the limitation of
using HIV non-replicating virus, highlight the actual uncertainty about the role of PARP-1
in retroviral infection.
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1.6.

Significance and Hypothesis
HIV-1, in common with all viruses, requires the concerted contributions of

numerous positively acting cellular factors and pathways to achieve efficient replication
[67]. Recent studies have revealed that the number of host proteins involved in the
response to viral infection exceeds 1000 for HIV-1 [68, 69]. Antiviral drugs, in addition to
target viral proteins, could be directed to inhibit or enhance positive or negative,
respectively, cellular regulators of viral replication. Drugs targeting cellular factors instead
of viral proteins are expected to encounter less viral resistance mechanisms because of
the higher genetic stability of host proteins as compared to viral proteins. It is well
established that the high rate of mutation of HIV-1 notoriously render this viruses
resistance to treatments. Then the strategy of targeting cellular cofactors of HIV-1
replication as therapeutic strategies is particularly promising.
My work is devoted to the functional characterization of PARP-1 in HIV-1 infection.
Our laboratory has identified the interaction of PARP-1 with LEDGF/p75 in two
independent proteomic experiments, LEDGF/p75 is an important cellular cofactor of HIV1 replication, and also has demonstrated that PARP-1 represses the expression of
retroviral vectors derived from Murine Leukemia Virus and HIV-1 in chicken cells [70].
This repressive function of PARP-1 requires the activity of Histone Deacetylases and
DNA methylases. Similarly, in Drosophila melanogaster PARP-1 represses the
expression of endogenous retrotransposons by promoting chromatin compactation at the
genome of these retroelements [71, 72]. However, the repressive role of PARP-1 on
retroviral gene expression has been demonstrated only in non-replicating retroviruses in
non-human cells. This work will increase our knowledge further by evaluating the
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implication of PARP-1 in HIV-1 replication in human CD4 T cells. I expect that after the
conclusion of my research we will definitively define the role of PARP-1 as a cellular
cofactor for HIV-1 replication.
The implication of PARP-1 in several biological processes that are important for
HIV-1 replication, including chromatin organization, transcriptional regulation, and DNA
repair, suggests that this enzyme could impact the HIV-1 life cycle at different steps.
In order to expand our knowledge on the potential role of PARP-1 in the retroviral
life cycle we have exploited two PARP-1 KO cellular models. We have determined the
effect of PARP-1 deficiency on the expression of Avian Leukemia Virus (ALV) by using
PARP-1 KO chicken B lymphoblastoid cells and we have also investigated the role of this
protein on HIV-1 replication, by using PARP-1 KO (and knockdown) Human CD4+ T
lymphoblastoid cells. Using these approaches, we have been able to support our
hypothesis that PARP-1 is implicated in the expression and replication of retroviruses.
More relevant yet, we have also been able to test and corroborate this hypothesis by
using PARP-1 inhibitors during the infection of human CD4+ T cell lines and human
primary CD4+ T cells.
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CHAPTER 2: Evaluating the effect of PARP-1 deficiency on Avian
Leukemia Virus expression in chicken cells
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2.1.

Introduction
As previously mentioned, at the beginning of this work the role of PARP-1 in HIV-

1 infection was not established. We hypothesized that one reason for this limitation was
due to the functional redundancy of PARP-1 found in mammalian cells [73, 74]. Therefore,
we thought that the study of PARP-1 functions in evolutionary simpler organisms that lack
this functional redundancy will be advantageous as previously shown in other PARP-1
functions [37, 71, 72]. In addition, PARP-1 functions identified in simpler organisms are
relevant to more complex organisms due to the high evolutionary conservation of PARP1 from Drosophila to humans[70].
In this study we took advantage of the functional and structural evolutionary
conservation of PARP-1 and we studied the role of the enzyme in the expression of an
endogenous retrovirus using the chicken B lymphoblastoid cell line DT40. These cells
exhibit low PARP-1 functional redundancy and are viable after PARP-1 knockout. DT40
cells naturally lack the PARP-2 gene, the closest PARP-1 paralog, and PARylation is
completely abrogated after PARP-1 knockout, indicating that the enzyme is the principal,
if not the only, PARP protein with enzymatic activity in these cells [75].
DT40 cells produce infectious Rous sarcoma virus (RAV-1), the retrovirus used to
generate the cell line [76] which is closely related to HIV since they belong to the same
family. Therefore, we decided to evaluate the effect of PARP-1 on RAV-1 gene
expression by determining the production of the virus by DT40 cells.
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2.2.

Materials and Methods

2.2.1. Cell Lines
DT40-derived wild-type (WT) and KO cell lines and a PARP-1 knockout
engineered to express human PARP-1 (KO h-1) were previously described[75] and were
kindly provided by Shunichi Takeda (Crest Laboratory, Department of Radiation Genetics,
Faculty of Medicine, Kyoto University, Kyoto, Japan). DT40-derived cells were cultured in
RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, 6% heat-inactivated
chicken serum, 2 mM L-glutamine, and 1% penicillin/streptomycin.
2.2.2. Immunoblotting
Cells (3x106) were lysed in 100 ul of Laemmli sample buffer (12mMTris-Cl,pH6.8,
0.4% SDS,2%glycerol,1% β-mercaptoethanol, 0.002% bromophenol blue), and 15 ul of
the sample was resolved in 10% Acrylamide by SDS-PAGE and transferred overnight to
polyvinylidene difluoride (PVDF) membranes at 100 mA at 4 °C. The membranes were
blocked in Tris-buffered saline (TBS) containing 10% milk for 1 h and then incubated with
the corresponding primary antibody diluted in TBS-5% milk-0.05% Tween 20 (antibody
dilution buffer). PARP-1 was detected with MAb 2-C-10 [77] (diluted 1/1,000), and PARP2 with a rabbit antibody (Santa Cruz sc-133886, diluted 1/500). As a loading control, antialpha-tubulin MAb (clone B-5-1-2; Sigma) was used at a 1/4,000 dilution. Membranes
were incubated overnight at 4 °C with anti-PARP-1 or -2, whereas anti-alpha tubulin MAb
was incubated for 2 h at 25 °C. Primary-antibody-bound membranes were washed in
TBS-0.1% Tween 20, and bound antibodies were detected with goat anti-mouse Ig-
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horseradish peroxidase (HRP) (Sigma) diluted 1/2,000 in antibody dilution buffer, followed
by chemiluminescence detection.
2.2.3. PAR ELISA
Protein-coupled or -uncoupled PAR was measured in cell lysates by ELISA
following the manufacturer instructions (Catalog # 4520-096-K; Trevigen). DT40 cells
were collected and washed in 1 ml of ice-cold 1X PBS by centrifugation at 1000 x g for 6
mins. The pellet was resuspended in 100 μl of cell lysis buffer supplemented with
protease inhibitors and incubated on ice for 15 minutes with periodic vortexing. Then,
SDS was added to the samples to achieve a final concentration of 1% and incubated at
100°C for 5 minutes. Once the cell extracts cooled to room temperature, 0.01 volume of
Magnesium Cation (catalog # 4520-096-12; Trevigen) and 2 μl of DNAse I (2 Units/μl,
catalog # 4520-096-07; Trevigen) were added, followed by incubation at 37°C for 90
minutes. To remove cellular debris, cell extracts were centrifuged 10,000 x g for 10
minutes at room temperature and then, without disturbing the pellet, the supernatants
(about 90 μl) were collected in a fresh tube for ELISA analysis.
2.2.4. Analysis of the production of RAV-1

DT40 cells are known to continuously produce and release infectious RAV-1 into
the supernatant [76]. Then we evaluated the amount of RAV-1 produced by DT40-derived
cells lacking or expressing PARP-1.
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2.3.

Results

2.3.1. Characterization of DT40 WT, KO and KO h-1 cell lines
DT40 B lymphoblastoid cell lines were characterized by determining the
expression of PARP-1 and PARP-2 proteins following an immunoblotting procedure. As
represented in Figure 2.1, PARP-1 protein is present in DT40 WT cells and DT40 KO h1 cells but not in DT40 KO cells. PARP-2 was not detected in any of the cell lines studied.
α-tubulin protein was immunoblotted as a loading control.

Figure 2.1 Immunoblotting of PARP-1 and PARP-2 in DT40 WT (lane a), KO (lane b), KO h-1 (lane c)
PARP-1 and PARP-2 proteins were detected in lysates from DT40 WT, KO and KO h-1 chicken cell lines
using human α-PARP-1 or human α-PARP-2 antibodies respectively. α-tubulin expression was used as a
loading control.

These results, as expected, show that PARP-1 is in fact the only PARP protein
expressed in chicken cells, at least by judging the deficiency of PARP-2 which is usually
the second most common PARP protein, and also corroborate the successfully
generation of a PARP-1 KO cell line. Human PARP-1 has also been efficiently expressed
in the DT40 KO cells.
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The expression levels of a protein do not always correlates with its enzymatic
activity. Since we were able to verify the deficiency of PARP-1 protein in DT40 KO cells
and the expression of human PARP-1 in DT40 KO h-1 cell lines we decided to investigate
the intracellular PARylation activity in those cells, considering that PARP-1 accounts for
most of PAR production in the cell, as we previously mentioned.

Figure 2.2 PARylation assay in DT40 WT, KO and KO h-1 cells
The amount of intracellular PAR units, expressed in pg/ml, was quantified in lysates from chicken DT40
WT, KO and KO h-1 cell lines.

Intracellular PAR levels, expressed in pg/ml of PAR, detected in our experiment
(Figure 2.2) show that the deficiency of PARP-1 in DT40 KO correlates with a drastically
decreased amount of PAR units in the cell. The amount of PAR detected in KO cells was
almost 20 times lower than in WT cells and the expression of human PARP-1 restored
the amount of synthetized PAR to comparable levels in WT cells.
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2.3.2. The production of RAV-1 is affected by the levels of PARP-1
DT40 cell lines were generated by infecting a chicken with RAV-1 [76]. These cells
in culture are known to continuously produce and release infectious avian Rousassociated virus type 1 (RAV-1) into the supernatant.
We reasoned that if PARP-1 is implicated in the expression of an integrated
retrovirus, the difference in PARP-1 expression between these cell lines would implicate
a difference in RAV-1 viral expression measured by the levels of viral reverse
transcriptase activity as an indicator of infectious viral particles.
The data in Figure 2.3 clearly indicate that the production of RAV-1 was affected
by the levels of PARP-1 in the producer cells. RAV-1 production was 2.5-fold and 12.5fold higher in PARP-1-null cells (KO cells) than in WT or KO h-1 cells, respectively. The
reason for a higher repression in viral expression when human PARP-1 was re-expressed
in previously PARP-1 KO chicken cells when compared to the repression of viral
expression observed in chicken WT cells could be due to human PARP-1 being more
restrictive than chicken PARP-1 or the fact that the human PARP-1 expression achieved
during the generation of the KO h-1 cell line was even higher than the observed in chicken
WT cells as depicted in the figure 2.1. These data demonstrated that PARP-1 modulates
the expression from the LTR promoter of an endogenous retrovirus.
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Figure 2.3 Analysis of RAV-1 retrovirus production in DT40 WT, KO, and KO h-1 cells
Reverse transcriptase levels were measured in DT40 WT, KO, and KO h-1 cells as an indicator of infectious
viral particles and expressed in fold increase.
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CHAPTER 3: Determining the role of PARP-1 in HIV-1 replication in
human cell lines
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3.1.

Introduction
One of the most exciting experimental approaches used to investigate the

influence of a particular host protein in viral replication is the generation of stable
knockdown or knockout cell lines with low expression or protein deficiency, respectively.
If a phenotype is observed in these cell lines with respect to the wild type, after infection,
then it could be inferred that the protein in question influences the life cycle of the virus.
The specificity of the protein in the observed effect can also be addressed by backcomplementing or re-expressing it in the deficient cell lines, in which case the wild type
phenotype should be restored.
We envisioned that the generation of PARP-1 KD and KO CD4+ T cell lines would
allow us to determine the influence of this protein in HIV replication by comparing the
infectivity of the virus in these cells with the infectivity in the PARP-1 back-complemented
counterpart. The use of specific PARP-1 inhibitors could also mimic or reproduce any
previously observed results in KD and KO cell lines after viral infection.
In order to address the possible mechanism linking PARP-1 with HIV replication
we decided to investigate the effect of PARP-1 deficiency on the early phase of the HIV
life cycle by infection of target cells with an HIV single round vector, VSV-G pseudotyped
virus. It is important to notice that these viruses enter the cell independently of
CD4/chemokine receptor and recapitulates all the steps of the HIV life cycle but do not
produce infectious particles because of the lack of HIV-1 envelop proteins, limiting the
infection to one round.
We generated a human PARP-1 knockdown (KD) and PARP-1 knockout (KO) cell
line in SupT1 cells, a CD4+ T-lymphoblastoid cell line that supports optimal HIV
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replication, then we proceeded to re-express the protein by using lentiviral vectors
generating the corresponding back-complemented lines. This exogenous PARP-1 cDNA
expressed in KD cells is engineered to have several silent point mutations allowing it to
escape the previously introduced shRNA but producing a wild type protein. In KO cells
PARP-1 was re-expressed with the wild type cDNA sequence. Similar levels of CD4 and
CXCR4 were verified by FACS analysis in the resulting PARP-1 deficient and backcomplemented cell lines. These cells were then used in HIV-1 infection experiments using
replication competent and incompetent viruses.
Considering the commercial availability of several PARP inhibitors that target
different domains of the protein, we also evaluated their effect on HIV-1 infection.
3.2.

Materials and Methods

3.2.1. Cell Lines
Human PARP-1 KD and control cells were generated by transduction of SupT1
cells with HIV-derived vectors produced with plasmids pTRIP EGFP shRNA PARP-1 and
pTRIP EGFP shRNA control. These plasmids were constructed by cloning shRNA
expression cassettes that contain PARP-1-specific or scrambled shRNA sequences at a
unique PpuMI site in pTRIP EGFP. The PARP-1-specific shRNA expression cassette was
generated by annealing oligonucleotides 5’-GatcccgAAGTATCCCAAAAAGTTCTttcaa
gagaAGAACTTTTTGGGATACTTttttttggaaa-3’ and 5’-agcttttccaaaaaaAAGTATCCCAA
AAAGTTCTtctcttgaaAGAACTTTTTGGGATACTTcgG-3’ and cloning them into the
pSilencer 2.1-U6 hygro expression plasmid (Ambion). Then, the U6 promoter and the
shRNA sequences were amplified by PCR with primers EE5 (sense; 5’-TATAGGG
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ACCCGT AAAACGACGGCCA GTGCC-3’) and EE6 (antisense; 5’-TATAGGGTC
CCGAATTCCCCAG TGGAAAGACG-3’) and cloned into pTRIP EGFP. Generated
PARP-1 KD cell lines were sorted for 10% highest eGFP expression and characterized
by western blot and FACS (CD4/CXCR4).
Human PARP-1 knockout (KO) cell lines were generated by transduction of SupT1
cells with HIV-derived vectors encoding a zinc finger nuclease (ZFN) expressed from a
CMV promoter, which specifically targets PARP-1. A CompoZr Knockout Zinc Finger
Nuclease kit specific for human PARP-1 was purchased from Sigma-Aldrich and the
included plasmid pZFN (4129bp) was digested with the restrictions enzymes NheI (697)
and XhoI (1917) to generate a fragment containing the PARP-1 specific zinc finger
domain and the nuclease domain of FokI. This fragment was cloned into pTrip eGFP used
to generate lentiviral vectors and target cells were infected followed by single cell cloning.
Generated PARP-1 KO cell lines were characterized by Western blot and
FACS(CD4/CXCR4)
For generation of PARP-1 BC cell lines with previously PARP-1 KD cells, the latter
cells were infected with a retroviral expression vector carrying a PARP-1 cDNA cassette
with several silent mutations to escape shRNA recognition. The escape mutations were
introduced by phusion PCR using the Thermo Scientific Phusion Site-Directed
Mutagenesis kit (Cat: F-541). Infection with a retroviral expression vector carrying PARP1 cDNA wild type was used to generate PARP-1 BC cell lines with previously PARP-1 KO
cells. In both cases an MLV retroviral vector (pJZ308) was used, so the gene expression
was driven from an MLV promoter. Cell lines were characterized by Immunoblotting and
FACS as previously described.
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SupT1 and HEK293T cells were grown in RPMI 1640 and DMEM, respectively. All
culture mediums were supplemented with 10% of heat-inactivated fetal calf serum, 2 mM
L-glutamine and 1% penicillin/streptomycin.
3.2.2. Retroviral Vectors
Previously described procedures [78] were followed for the production of the
different retroviruses used in this study. Briefly, 293T cells were co-transfected by
calcium-phosphate with 15 µg of the expression plasmids and 5 µg of the Vesicular
Stomatitis Virus glycoprotein G expression plasmid, pMD.G. At 48 h post-transfection, the
viral supernatants were harvested and concentrated by ultracentrifugation at 124,750 x g
for 2 h on a 20% sucrose cushion. Viral aliquots were stored at -80 °C until use.
HIVpNL4-3 wild type virus was produced by transfection of 15 μg of the
corresponding expression plasmids in HEK293T cells, as previously described.
3.2.3. Immunoblotting
3x106 cells were lysed in 100 μl of Laemmli sample buffer (12 mM Tris-Cl pH 6.8,
0.4% SDS, 2% glycerol, 1% β-mercaptoethanol, 0.002% bromophenol blue), and 15 μl of
the sample resolved by SDS-PAGE, and transferred overnight to PVDF membranes at
100 mAmp at 4 °C. Membranes were blocked in TBS containing 10% milk for one hour
and then incubated with the corresponding primary antibody diluted in 1X TBS, 5% milk,
0.05% Tween 20 (antibody dilution buffer). PARP-1 protein was detected with a mouse
anti-PARP-1(C2-10) antibody (Santa Cruz Biotechnology, Cat: sc-53643). Membranes
were incubated overnight at 4 °C with previously described primary antibody, then
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washed in 1X TBS, 0.1% Tween 20 and bound antibodies detected with goat anti-mouse
Igs-HRP.
3.2.4. Cell sorting and FACS analysis
eGFP expressing SupT1 cells were sorted for 10% highest expression at the
Texas Tech University Health Science Center molecular biology core facility using a BD
FACSJazz cell sorter. The expression of CD4/CXCR4 receptors on PARP-1 KD and KO
cells was analyzed by flow cytometry after surface staining of the cells with purchased
antibodies from BD Pharmigen (APC mouse Anti-Human CD184 Cat:560936, APC
mouse Anti-Human CD4 Cat:561840).
3.2.5. HIV-1 replication assays
PARP-1 KD/Scramble/BC and KO/BC SupT1 cells (0.25 x 10 6 cells in 2 ml RPMI
1640) were infected with HIVpNL4-3 virus. Twenty-four hours after infection, the cells
were washed three times by centrifugation in 10 ml of culture medium to remove the input
virus and fresh media was added. Cell supernatant was then collected at different days
post-infection and used for HIV-1 p24 quantification by ELISA.
3.2.6. HIV-1 extracellular p24 ELISA
HIV-1 p24 levels were determined by a sandwich ELISA (ZeptoMetrix Corporation,
catalog number 0801008) following the manufacturer instructions. Briefly, 200 μl of the
viral samples were diluted appropriately and incubated on the ELISA wells overnight at
37 °C. Unbound proteins were removed by washing the wells six times with 200 μl of
washing buffer, and bound HIV-1 p24 was detected by incubating each well with 100 μl
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of the anti-HIV-1 p24 secondary antibody for one hr. Unbound antibodies were removed
by washing as described above and bound antibodies were detected by incubating each
well with 100 μl of substrate buffer for 30 minutes at room temperature until the reaction
was stopped by adding 100 μl of stop solution into each well. The absorbance of each
well was determined at 450 nm using a microplate reader.
3.2.7. PAR ELISA
Protein-coupled or uncoupled PAR was measured in cell lysates by ELISA
following the manufacturer instructions (Catalog # 4520-096-K; Trevigen). SupT1 cells
were collected and washed in 1 ml of ice-cold 1X PBS by centrifugation at 1,000 x g for
6 mins. The pellet was resuspended in 100 μl of cell lysis buffer supplemented with
protease inhibitors and incubated on ice for 15 minutes with periodic vortexing. Then,
SDS was added to the samples to achieve a final concentration of 1% and incubated at
100°C for 5 minutes. Once the cell extracts cooled to room temperature, 0.01 volume of
Magnesium Cation (catalog # 4520-096-12; Trevigen) and 2 μl of DNAse I (2 Units/μl,
catalog # 4520-096-07; Trevigen) were added, followed by incubation at 37°C for 90
minutes. To remove cellular debris, cell extracts were centrifuged 10,000 x g for 10
minutes at room temperature and then, without disturbing the pellet, the supernatants
(about 90 μl) were collected in a fresh tube for ELISA analysis.
In experiments that evaluated the effect of PARP inhibitors, the cells were collected
by centrifugation at 1,000 x g for 6 minutes and the pellet was resuspended in 1 ml of icecold 1X PBS. A fraction (100 μl) of the cell suspension was used to measure ATP levels
(Cell Titer-Glo Assay; Promega) to determine cell viability. The remaining cells (900 μl)
were used for PAR quantification as indicated above.

41

3.2.8. Pharmacological inhibition of PARP
SupT1 cells were treated with several PARP inhibitors (selection based on
enzymatic inhibitory activity) for 24 hours and then challenged with HIVpNL4-3, a
replication competent virus. Viral input and drugs were washed 24 hours later. The
supernatant from infected cells was collected for several days and then HIV-1 replication
(p24 ELISA) and cell viability (ATP levels) were measured as described above. The PARP
inhibitors set (Cat No. 528820, EMD) included 3-Aminobenzamide (ABA), 5-Iodo-6amino-1, 2-benzopyrone (II), and 1, 5-Isoquinolinediol (NU).
3.2.9. HIV single round infectivity assay
PARP-1 KO/BC cells were plated at 1x105 cells in 500µl of RPMI1640 culture
medium in 24-well plates and infected with an HIV single round infection vector HΔEluc,
expressing a luciferase reporter gene from the viral LTR. Four days post-infection, cells
were collected by centrifugation at 1000g for six minutes and the pellet resuspended in
200 μl of PBS. Half of the sample was mixed with 100 μl of luciferase substrate (BrightGlow™ Luciferase Assay System, Promega) and the other half with 100 μl of cell viability
substrate (CellTiter-Glo® Assay, Promega). Cell lysates were incubated for 10 minutes
at room temperature in the dark and then luminescence measured in triplicate in 50 μlsamples using a microplate luminometer reader.
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3.3.

Results

3.3.1. Generation of PARP-1 KD, Ctrl, BC and KO cell lines
As depicted in Figure 3.1, we have been able to generate a PARP-1 KD cell line by
targeting this protein with a specific shRNA cloned into a lentiviral vector and a PARP-1
KO cell line by using a zinc finger nuclease. Notice the low level of PARP-1(116 kDa)
expression in KD cells and the lack of expression in KO cells when compared with the
expression in Supt1 cells. These two characterized cell lines are just a representation of
our results since several cell lines have been generated. α-tubulin was used in this blot
as a loading control and as expected the bands are similar in both cell lines. The
expression of CD4/CXCR4 surface markers was analyzed in these cell lines by flow
cytometry and we did not find any difference (data not shown).
The Western blot illustrated in Figure 3.2 shows the expression of PARP-1 in
SupT1 control cells, KD, KO and BC cell lines. The BC cell line generated by reexpression of PARP-1 in KD cells displays an approximately 30% restoration of PARP-1
levels as determined by a gel density analysis software. Ultimate efforts to generate a
higher PARP-1 expressing BC cell line have failed for unknown reasons. The BC cell lines
generated with previously PARP-1 KO cells show comparable expression of the protein
with respect to the expression in control cells. Tubulin was used as a loading control and
it is evident that loading differences are not significant. Cell lines were characterized by
CD4 and CXCR4 expression and no differences were observed.
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Figure 3.1 Immunoblotting of PARP-1 in Ctrl, KD and KO cells.
Human PARP-1 was detected in cell lysates from PARP-1 Ctrl, KD and KO cells lines by using an α-human
PARP-1 antibody. α-tubulin was used as a loading control.

Figure 3.2 Immunoblotting of PARP-1 in Ctrl, KD, KO and BC cells
Human PARP-1 was detected in cell lysates from PARP-1 Ctrl, KD, KO, and the respective BC cell lines
by using an α-human PARP-1 antibody. α-tubulin was used as a loading control.
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3.3.2. The deficiency of PARP-1 enhances HIV-1 replication in CD4+ T cell lines
Figure 3.3 represents a replication curve of the HIV virus in PARP-1 KD, BC and
control cells. Supernatant from infected cells was taken at different time points and the
amount of p24 present was analyzed by ELISA. The results show that the deficiency of
PARP-1 in PARP-1 KD cells lines enhances the permissivity of these cells to HIV viral
infection when compared to control cells. Notice that the HIV p24 values have been
expressed in a logarithmic scale, which means the actual differences in p24 levels are
very dramatic. Contrary to this finding, by re-expressing PARP-1 in KD cell lines we were
able to partially restore the phenotype observed in control cells, consisting in a reduction
of the viral replication rate. We hypothesize that the BC cell lines do not behave as control
cells because of the low PARP-1 protein expression (30% of wild type cells) achieved in
KD cells (Fig. 3.2). The difference in viral replication between the KD and BC cell lines
persists during almost the entire collection period but after 16 days the p24 levels become
similar which might be explained by the fact that the target cells are dying due to the
cytopathic effect of HIV-1 replication. Similar to the results observed in PARP-1 KD and
BC cell lines, in Figure 3.4 a higher replication rate in PARP-1 KO cell lines was detected
compared to the replication in PARP-1 BC cell lines. Also notice the p24 values were
plotted using a logarithmic scale.
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Figure 3.3 HIV replication assay in PARP-1 Ctrl, KD, and BC cells
Infectivity was measured by determining the levels of HIV p24 protein in supernatant of infected cells at different time
points. Only one representative experiment hast been presented.
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Figure 3.4 HIV replication assay in PARP-1 KO and BC cells
Infectivity was measured by determining the levels of HIV p24 protein in supernatant of infected cells at different time
points. Only one representative experiment hast been presented.
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3.3.3. Inhibitors targeting the PARP-1 DNA binding domain impair HIV replication
In Figure 3.5 we have represented the parylation activity of SupT1 cells in the
presence of several PARP inhibitors, by detecting the amount of PAR in the cell. ABA, 5Iodo-6-amino-1, 2-benzopyrone (II) and NU have a similar inhibitory effect and therefore
we selected them as candidates for future HIV replication assays.
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1000
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800

NU
600
400
200
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PARP Inhibitors

Figure 3.5 Parylation assay in SupT1 cells in the presence of PARP inhibitors
Several PARP inhibitors were tested on their ability to inhibit PARP by detecting a reduction in parylation activity. The
amount of PAR was expressed in pg/ml.
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Cells were infected in the presence of these inhibitors or DMSO, and 24 hrs later
the compounds and virus were removed and replication was followed for several days.
Importantly, inhibitor II caused a significant increase in HIV replication rate when
compared to the replication in the presence of the vehicle DMSO or in cells treated with
the other two PARP-1 inhibitors (Figure 3.6). This enhancement in replication is significant
considering that the levels of p24 are expressed using a logarithmic scale.
Most of PARP inhibitors, like ABA and NU, block the activity of the PARP enzymes
by mimicking the nicotinamide moiety of nicotinamide adenine dinucleotide (NAD) and
binding to the PARP catalytic site, which either directly blocks PARP enzymatic activity
or causes PARP to accumulate on DNA (known as PARP trapping). One downside to this
mechanism of action is that they are broad spectrum and target not just PARP-1 and
PARP-2, but other members of the PARP family[79].
Inhibitor II, on the other side, is specific for PARP-1 and impairs its DNA binding
activity. It belongs to the family of coumarins, and in the cell undergoes rapid oxidation at
the 6-amino position to form 5-iodo-6-nitroso-1, 2 benzopyrone which is the reactive
species. The latter binds with high affinity to zinc-fingers of enzyme PARP-1 and by
oxidizing the SH groups of these zinc fingers to -S-S groups thus eliminates or ejects zinc
from PARP-1. Zinc ejection inactivates PARP-1 since the enzymatic process is
dependent on DNA, [80].
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Figure 3.6 HIV replication assay in SupT1 cells in the presence of PARP-1 inhibitors
Infectivity was measured by determining the levels of HIV p24 protein in supernatant of infected cells at different time
points. Despite observing similar PARP-1 inhibitors effect on HIV replication in four independent experiments performed
only one of them has been presented in this figure because we have not been able to consistently detect the inhibitors
effect after the same number of days post-infection. Several independent experiments have been planned in order
overcome this issue.

3.3.4. PARP-1 does not affect the infection of single-round HIV-1 virus
To determine the step of the viral life cycle affected by PARP-1 we characterized
the susceptibility of PARP-1 KO and BC cells to single-round infection HIV-1 expressing
luciferase from the viral promoter. Figure 3.7 shows the amount of intracellular reporter
protein luciferase, expressed from the HIV LTR promoter, quantified after four days of
infection. Only two independent experiments are represented but the infection was
performed with different clones and several replicates. Surprisingly, no significant
difference in the infection of KO and BC cells was observed in these experiments (Figure
3.7), which is in marked contrast with the effect of PARP-1 deficiency HIV-1 replication
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that we previously observed. Importantly, similar results were obtained with PARP-a KD
and BC cells and with SupT1 cells treated with inhibitor II.

Figure 3.7 HIV single round infection of PARP-1 KO and BC SupT1 cells.
A single round HIV virus carrying a luciferase reporter gene was used. Luciferase was measured 4 days after infection.

Since single-round infection HIV-1, contrary to wild type HIV-1, bypasses
CD4/CXCR4-mediated entry and does not undergoes multiple rounds of infection, these
results strongly suggest that PARP-1 deficiency enhances HIV-1 replication by
modulating events related to CD4/CXCR4-mediated entry, or the infectivity of the
produced viruses.
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CHAPTER 4: Determining the role of PARP-1 on HIV-1 replication in
human primary central memory T cells
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4.1.

Introduction
Our previous data is indicative that PARP-1 deficiency promotes HIV-1 replication

in human CD4+ T cell lines. Therefore, we hypothesized that PARP-1 inhibition could
stimulate viral replication in cells that promote HIV-1 latent infection. To evaluate this
hypothesis we used determine the role of PARP-1 in central memory T cells that represent
one of the major latency compartments in infected individuals. The cells were generated
in vitro following a well-established in vitro paradigm of viral latency [60]. Briefly, naïve
CD4+ T cells were purified from peripheral blood, activated in vitro with CD3/CD28
stimulation in the presence of IL2, and then infected with HIV-1. Subsequently, infected
cells were expanded with IL2 in the absence of CD3/CD28 stimulation to allow the cells
to return to a quiescence state. During quiescence reentry HIV-1 latency is established
[60]. We adapted this model to evaluate the role of PARP-1 in HIV-1 latency by
determining the effect of inhibitor II on the replication of HIV-1 during the quiescence reentry period. We expected that if PARP-1 is implicated in latency establishment, HIV-1
will replicate better in the cells treated with the inhibitor than in the DMSO-treated cells.
4.2.

Materials and Methods

4.2.1. Isolation of peripheral blood mononuclear cells (PBMC)
Peripheral blood was collected from unidentified, healthy donors in heparin
containing collection tubes and later transferred to 50 ml conical tubes. An equal volume
of phosphate buffer saline (DPBS: Dulbecco’s Phosphate-Buffered Saline, 1X without
calcium and magnesium; Mediatech-Cellgro -21-031-CV) was used to wash the collection
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tubes and then mixed with the previous blood sample. Half the total volume per tube of
Lymphocyte separation media (LSM) (Fisher #MT25072CV) was then quickly added with
a pipet to the bottom of each 50 mil tube. Once all tubes have pipets with LSM in them,
carefully put pipet back onto the pipet-aid without removing it from the tube and slowly
expel the remaining LSM; carefully remove the pipet from the tube and discard. Centrifuge
at 400 x g for 30 minutes at 18-20 C (brake off). Aspirate down to the lymphocyte layer
leaving enough liquid so as not to disturb the layer (approximately 5-7 ml above the layer
should be plenty). Use a 5-ml pipet to collect all the mononuclear cells from the interface
in a circular motion and transfer to a new 50ml tube. Add 2X volume of PBS, mix well and
centrifuge at 250 x g for 10 minutes at room temperature. Aspirate the supernatant, being
careful not to disrupt the pellet. Wash and combine the tubes to one tube using PBS.
Centrifuge at 250 x g for 10 minutes at room temperature. Resuspend in 5-10 ml of
complete media.
4.2.2. Isolation of Naïve CD4+ T cells from PBMC
This step was performed by using the Naïve CD4+ T cell Isolation kit II from
Miltenyi Biotec (Order no. 130-094-131). Basically we count 1x108 PMBC, centrifuge the
cell suspension at 300 x g for 10 minutes and then aspirate the supernatant completely.
We then resuspend the cell pellet in 40 μL of buffer per 10⁷ total cells and add 10 μL of
Naive CD4+ T Cell Biotin-Antibody Cocktail II per 10⁷ total cells. Mix well and incubate for
5 minutes in the refrigerator (2−8 °C). After incubation we add 30 μL of buffer per 10⁷ total
cells and 20 μL of Naive CD4+ T Cell MicroBead Cocktail II per 10⁷ total cells. Mix well
and incubate for an additional 10 minutes in the refrigerator (2−8 °C). Finally we proceed
to magnetic separation by using the Miltenyi Biotec LS columns provided with the kit and
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we collect the flow-through containing unlabeled cells, representing the enriched naïve T
cells.
4.2.3. Activation of Naïve CD4+ T cells
After Isolation, naïve CD4+ T cells were activated as previously described by
Bosque and Planelles[81]. 5x105 cells were stimulated with 5x105 beads coated with
αCD3 and αCD28 antibodies (Dynabeads CD3/CD28 T cell Expander, Dynal/Invitrogen)
in 1 ml of complete medium. To ensure homogenous activation of the cells, 100 ul of the
cell mixture, together with beads were plated in a 96-well, round bottom plate (BD Falcon,
Bedford, MA) and incubated for 3 days at 37 °C. After activation, cells were resuspended
to remove clumps and Dynabeads were removed using a magnet. Activated T cells were
re-plated at 1x106 cells/ml in complete medium with 30 IU/ml of rIL-2 (AIDS Research and
Reference Reagent Program) for 4 days at 37 °C. Medium and rIL-2 were replaced every
2 days.
4.2.4. Infection of activated T cells with HIV wild type in the presence of PARP-1
inhibitors
Activated T cells (7 days after stimulation with αCD3/CD28) were infected by
spinoculation (spinoculation dramatically increases the adsorption of HIV-1 to T cells) with
HIV wild type virus in the presence of DMSO or inhibitor II (INH 2BP). Spinoculation was
performed in a Sorvall Super T21 using an ST-H750 rotor at 2900 rpm (1,741g) during 2h
at 37 °C. The virus and DMSO/II containing supernatant was removed and cells kept in
culture at 1x106 cells/ml in complete medium with 30 IU/ml of rIL-2 at 37 °C during an
additional 7-day period in the absence of stimulatory beads to allow activated cells to
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return to a quiescence state. At days 3, 5 and 7 post-infection, media and rIL-2 were
replaced and cells were kept at a density of 1x106 cells/ml. Supernatant was collected at
different time points and used to measure extracellular p24 levels by ELISA.
4.2.5. HIV-1 extracellular p24 by ELISA
The levels of HIV-1 extracellular p24 were measured by using the ZeptoMetrix p24
ELISA kit as previously described in section 3.2.6
4.3.

Results

4.3.1. The deficiency of PARP-1 enhances HIV-1 replication in primary human CD4
T cells
We have previously demonstrated that the deficiency of PARP-1 enhances the
expression of an integrated retrovirus in chicken cells. In human CD4 T cell lines we also
showed that HIV replication is improved when PARP-1 is not present. Here we show for
the first time that in primary human CDT cells, the main target for HIV replication, the use
of inhibitors targeting the DNA binding domain of PARP-1, but not the catalytic domain,
enhances HIV replication.
As previously mentioned, it has been proposed that CD4 primary T cells can be
used as model to study HIV latency. CD4 T cells must be activated in vitro with CD3/CD28
stimulation in the presence of IL2, and then infected with HIV-1 while expanded with IL2
but in the absence of CD3/CD28 stimulation. Under these conditions infected cells return
to a quiescence state where HIV-1 latency is established.
We rationalized that if inhibitors targeting the DNA binding domain of PARP-1 were
able to enhance HIV viral replication in human CD4 T cell lines it would be possible that
the use of the same inhibitors during the infection of previously activated primary human
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CD4 T cells under conditions that normally promote latency now would cause an
enhancement in HIV replication.
Data in Figure 3.8 indicates that inhibitor II enhances HIV-1 replication in primary
CD4+ memory T cells and that the effect is observed as early as two day post-infection
but it is still observed after five days after infection. Viral replication was followed for
several days but there was a dramatic decay in p24 values after five days post-infection
associated with cell death due to viral replication. Since these cells are prone to establish
a latent viral reservoir, the data also suggest an implication of PARP-1 in viral latency
establishment.

Figure 3.8 HIV replication assay in human primary CD4 T cells
The assay was performed in the presence of either ence of DMSO or inhibitor II. Infectivity was measured
by determining the levels of HIV p24 protein in supernatant of infected cells at different time points. Results
correspond to one donor and are similar to the results obtained with a second donor.
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CHAPTER 5: Discussion
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A key pharmacological strategy for treating individuals living with HIV has been to
simultaneously target multiple virus-encoded enzymes required for replication to
overcome emergence of drug resistance. A parallel therapeutic strategy is targeting host
factors required for the HIV life cycle. Such host proteins represent therapeutic targets
that are not plagued by the twin problems of viral diversity and escape mutation that
interfere with the effectiveness of conventional antiretroviral drugs. We anticipate that HIV
would be hard-pressed to evolve resistance to drugs targeting cellular proteins, because
it would have to evolve a new capability, not simply mutate a drug-binding site. Therefore,
the identification of host factors implicated in HIV-1 infection (the focus of this work) is
important.
Previous reports addressing the role of PARP-1 in HIV infection have resulted in a
confusing interpretation of the actual requirement of this protein for completion of the viral
life cycle. As we mentioned before, it could be attributed to the PARP functional
redundancy in mammalians cells, highlighting the necessity to exploit simpler study
models. Our findings in chicken cells[70], demonstrate that the expression of an
endogenous retrovirus( RAV-1) is higher in cells lacking PARP-1(KO) than in wild type
cells, and this phenotype can be reverted by expressing human PARP-1 in the KO cells.
Thus, PARP-1 protein in chicken cells has an inhibitory effect on the expression of this
endogenous retrovirus. Though this result is not directly related to HIV, it is compelling
evidence since both viruses belong to the same family; in fact it determined our decision
to investigate the effect of PARP-1 in HIV infection of human cells. It is also worth to
mention that the transcription of RAV-1 in the cell takes place from an LTR promoter,
similarly to the natural transcription of HIV in infected targets. Despite the differences
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between the LTR promoters between both viruses, it is more probable to expect that the
mechanisms governing the PARP-1 effects would be similar in HIV infection.
We have also demonstrated that PARP-1 is a host protein implicated in HIV
replication in human cells. This conclusion has been supported by analyzing the effect of
PARP-1 deficiency or inhibition of its DNA binding properties in viral replication in human
cells. Our results clearly establish that PARP-1 has an inhibitory effect on the HIV-1
replication.
By investigating single-round infection HIV-1, we have determined that PARP-1
affects an event linked to CD4/CXCR4-mediated entry, or the infectivity of the viruses
produced. These data also demonstrated that the main reason why the important role of
PARP-1 in HIV-1 biology has been overlooked is because all the previous attempts
(including us) of defining a role of this protein in HIV-1 infection have been done by
analysis of single-round infection HIV-1.
PARP-1 inhibitors are an emerging class of agents that have the potential to play
an important role in the treatment of a variety of cancers. Several of them are on trial for
future use in humans but it turns out very interesting that little is known about the effect
that they could have on HIV-1 infection. The majority of PARP-1 inhibitors target the
catalytic activity of the protein, and the development of inhibitors affecting its DNA binding
function has been largely neglected. Since inhibitors targeting the catalytic domain of
PARP-1 did not influence the infectivity of HIV but the presence of inhibitor II during the
infection caused enhancement, it is safe to conclude that the relation between PARP-1
and HIV is independent of the catalytic activity of this protein.

59

In regards to determining the role of PARP-1 on HIV-1 replication in primary central
memory T cells, it is worth to mention that no study of the implication of PARP-1 in the
replication of HIV-1 wild type in primary human CD4+ T cells have been reported so far;
therefore our work is the first to address this question. Importantly, our data suggest that
PARP-1 is implicated in latency establishment in central memory CD4 T cells.

60

CHAPTER 6: Future Directions
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The main line of investigation we will follow in the future should be to investigate
the mechanisms of action implicated in the influence of PARP-1 during HIV-1 replication.
Knowing that the PARP-1 DNA binding domain, but not the catalytic domain,
determines the influence of this protein in viral replication is a key piece of information we
should exploit by site specific directed mutagenesis since the generation of mutants would
allow us to determine particular regions in this domain that are more important. This
investigation will show us if the protein primary structure is determining the viral restriction
activity or if it relies on protein conformation rather than protein sequence.
The analysis of PARP-1 influence during the late phase of the HIV life cycle should
be addressed by studying the virus produced after transfection of HEK293 cells lacking
this protein. As previously mentioned, this process recapitulates the late events of the
viral cycle. We will generate PARP-1 KO HEK293 cells and transfect them with plasmids
capable to generate a replication competent virus. We will measure viral production and
infectivity of the virus produced from HEK293 KO and HEK293 WT. If PARP-1 is
influencing the late phase of the HIV life cycle we should observe a higher viral production
from cells lacking PARP-1. Less viral infectivity could be also observed when the virus
produced from HEK293 KO is used to infect other cells. This information will be very
useful considering this approach has not been exploited in any PARP-1 published
research concerning HIV.
Another hypothesis to be tested is that PARP-1 could be affecting the infectivity of
viral particles produced after a round of infection. This effect would imply a difference in
the overall viral replication rate when a replication competent virus is used for infection.
PARP-1 could affect the infectivity of viral particles by different manners, including the
modification of viral proteins, or the packaging of other cellular factors into the virion,
among others. We are planning on determining the infectivity of single-round and multipleround infection viruses produced in PARP-1 deficient cells.
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Also an important goal is to determine if the reason behind a difference in infectivity
is a differential viral evolution depending on the presence or absence of PARP-1. It is well
recognized that the human immunodeficiency virus is one of the fastest evolving entities
known and that both cellular and viral factors influence this process. We propose to
sequence the main viral structural proteins Gag, Pol and Env in viruses collected from
PARP-1 KO and PARP-1 BC cells and determine the presence of possible viral
advantageous mutations in those strains produced in the absence of PARP-1. Accessory
and regulatory proteins could also be compared in the future.
The interplay between HIV-1 and plasma membrane signaling has been previously
addressed and it has been proposed that it could probably have a higher impact that we
think in terms of viral fitness and pathogenicity. In the future we would like to investigate
if PARP-1 influences HIV replication by means of interfering CD4/CXCR4 signaling that
regulates HIV gene expression. We plan to determine whether PARP-1 can regulate
CD4/CXCR4-induced modulation of transcription factors like NF-κB and SP1 by
performing Western blot with lysates from PARP-1 KO and PARP-1 BC cells infected with
an HIV replication competent virus.
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